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Objectives. This study attempted to determine the long-term 
outcome of verapamil-sensitive sustained left ventricular tachy- 
cardia in patients without apparent structural heart disease. 
Background. Several types of idiopathic ventricular tachycardia 
have been reported, and their clinical, electrophysiologic and 
electropharmacologic characteristics are different. It is possible 
that the prognosis of each type of ventricular tachycardia might 
also be different. 
Methods. We studied mortality and morbidity in 37 consecutive 
patients (27 male, 10 female; mean [-+SD] age 33 -+ 14 years) with 
verapamil-sensitive sustained left ventricular tachycardia who had 
no apparent structural heart disease. Patients were followed up for 1 
to 13 years (mean 5.8). Verapamil repeatedly terminated ventricular 
tachycardia n all patients. Ventricular tachycardia originated from 
the inferior and inferoseptal regions of the left ventricle in 33 patients 
and the superior and superioseptal regions in 4. Severity of ventric- 
ular tachycardia was classified according to the extent o which 
symptoms limited daily activities. Ventricular tachycardia was mild 
(minimal limitation) in 14 patients, moderate (some limitation) in 17 
and severe (severe limitation) in 6. 
Results. Fourteen patients with mild ventricular tachycardia 
were followed up without any drug therapy, and the ventricular 
tachycardia remained mild in all patients. Antiarrhythmic ther- 
apy was initiated empirically in the 23 patients with moderate and 
severe ventricular tachycardia (verapamil in 20, propranolol in 2, 
digoxin in 1). Moderate ventricnlar tachycardia became mild 
ventricular tachycardia after drug therapy in all patients, but the 
six patients with severe ventricular tachycardia showed no im- 
provement. The six patients with severe ventricular tachycardia 
had nonpharmacoiogic therapy (cryosurgery in one, catheter 
ablation in four, antitachycardia p cing device in one). During the 
follow-up period, all patients remained alive except for one who 
died suddenly after implantation of an antitachycardia p cing 
device. 
Conclusions. 1)The long-term prognosis of verapamil-sensitive 
sustained left ventricular tachycardia n patients without appar- 
ent structural heart disease is good. 2) Verapamil is the drug of 
choice for alleviating symptoms, but nonpharmacologic therapy is 
necessary in some patients. 
(J Am Coil Cardiol 1995;25:54-8) 
Idiopathic ventricular tachycardia s usually defined as ventric- 
ular tachycardia that occurs in patients without apparent heart 
disease or any identifiable predisposing cause of arrhythmia. 
The prognosis of patients who have ventricular tachycardia 
without apparent structural heart disease is believed to be 
good (1,2), but occasional sudden cardiac deaths have been 
described (1,3). 
Several types of idiopathic ventricular tachycardia have 
been reported (4-9), and their clinical and electrophysiologic 
characteristics are quite different. Thus, it is possible that the 
prognosis might also vary according to the type of idiopathic 
ventricular tachycardia. During the past 15 years, we have 
identified agroup of patients with idiopathic ventricular tachy- 
cardia originating from the left ventricle that is sensitive to 
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verapamil (6), but the long-term prognosis of this particular 
group of patients has been unclear. Thus, the purpose of this 
study was to determine the long-term outcome of verapamil- 
sensitive sustained left ventricular tachycardia in patients 
without apparent structural heart disease. 
Methods  
Patients. The study included 37 patients (27 male, 10 
female; mean age 33 years, range 12 to 68) seen at the National 
Cardiovascular Center between January 1979 and April 1992 
who met the following inclusion criteria: 1) electrocardio- 
graphically documented recurrent sustained monomorphic 
ventricular tachycardia originating from the left ventricle; 
2) no apparent structural heart disease; and 3) repeated 
termination of ventricular tachycardia by verapamil (Fig. 1). 
Ventricular tachycardia was diagnosed using standard elec- 
trocardiographic (ECG) criteria and confirmed from His bun- 
dle electrograms. The origin of ventricular tachycardia was 
determined by identifying the earliest ventricular activation 
site during ventricular tachycardia or by pace mapping during 
sinus rhythm. The presence of sustained ventricular tachycar- 
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Figure 1. Electrocardiograms show- 
ing ventricular tachycardia. Top, Be- 
fore administration f verapamil. 
Middle, After 2 mg of intravenous 
verapamil. Note that he ventricular 
tachycardia r te is slowed and that 
atrioventricular dissociation is now 
apparent (arrows indicate atrial ac- 
tivity). Bottom, After 5 mg of intra- 
venous verapamil has terminated the 
ventricular tachycardia. 
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dia was confirmed by ECG monitoring, and spontaneous 
termination was not recognized in any of the patients. 
The absence of organic heart disease was diagnosed on the 
basis of 1) normal findings on cardiac examination; 2) normal 
findings on the rest ECG and chest X-ray film; 3) lack of any 
significant ST depression or ST elevation during or after a 
submaximal treadmill exercise test; and 4) normal findings on 
the echocardiogram and radionuclide angiogram. The absence 
of organic heart disease was further confirmed by normal 
findings on coronary angiography, left ventriculography and 
right ventriculography in 17 patients. 
Severity of ventricular tachycardia was classified according 
to the extent o which symptoms limited daily activities: mild 
(minimal limitation), moderate (some limitation) and severe 
(severe limitation). 
Antiarrhythmic therapy was initiated empirically in patients 
with moderate or severe ventricular tachycardia. Patients were 
followed up for 1 to 13 years (mean 5.8) from hospital 
discharge to time of death or the last day of the study. The 
response of ventricular tachycardia to drug therapy was eval- 
uated during the follow-up period, and the efficacy of nonphar- 
macologic intervention was also studied. 
Statistics. The survival curve was obtained using the 
Kaplan-Meier method. 
Results 
Table 1 shows the clinical profile and follow-up data of all 
study patients. The age at onset of ventricular tachycardia was 
10 to 19 years in 14 patients, 20 to 29 years in 11, 30 to 39 in 
3, 40 to 49 years in 6, 50 to 59 years in 1 and >60 years in 2. 
The QRS configuration during ventricular tachyeardia was 
right bundle branch block with left-axis deviation in 33 patients 
(Fig. 2A), and their ventricular tachycardia originated from the 
inferior and inferoseptal regions of the left ventricle. The QRS 
configuration during ventricular tachycardia was right bundle 
branch block with right-axis deviation in the other four patients 
(Fig. 2B), and the origin of their ventricular tachycardia was 
the superior and superoseptal region of the left ventricle. 
Fourteen patients were classified as having mild, 17 had 
moderate and the remaining 6 had severe ventricular tachy- 
cardia. The 14 patients with mild ventricular tachycardia were 
followed up without any drug therapy. In all 14 patients, 
ventricular tachycardia remained mild, or symptomatic ventric- 
ular tachycardia ceased during the follow-up period. Antiar- 
rhythmic therapy was initiated empirically in the patients with 
moderate and severe ventricular tachycardia. Verapamil (160 
to 320 mg/day) was given to 20 patients either alone or in 
combination with other drugs (procainamide [1.5 to 2.0 g/day] 
in 3, propranolol [40 to 120 mg/day] in 2 and digoxin 
[0.25 rag/day] in 1). Propranolol (40 to 120 rag/day) adminis- 
tration alone was initiated in two patients and digoxin alone in 
one. In both patients taking digoxin, the effectiveness of this 
drug was confirmed by an electrical stimulation test that 
showed that ventricular tachycardia became noninducible dur- 
ing digoxin therapy. Of the 23 patients in whom antiarrhythmic 
drugs were initiated, 6 became free of symptomatic ventricular 
tachycardia, and ventricular tachycardia became mild in an- 
other 11. However, all six patients with severe ventricular 
tachycardia continued to have ventricular tachycardia episodes 
that severely limited their daily activities despite various drug 
regimens. 
Accordingly, patients with severe ventricular tachycardia 
had nonpharmacologic therapy. Cryoablation was performed 
in one patient (Patient 31) and catheter ablation in four 
patients (Patients 22, 25, 32 and 36); an antitachycardia device 
was implanted in one patient (Patient 8). Three patients with 
catheter ablation (Patients 25, 32 and 36) and one with 
cryoablation (Patient 31) became free of symptomatic ventric- 
ular tachycardia fter these procedures. One patient with 
catheter ablation (Patient 22) had recurrent ventricular tachy- 
cardia that was controlled by verapamil therapy. The patient 
with the implanted antitachycardia device died suddenly at 
home on the day of discharge from hospital. Actuarial survival 
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Table 1. Clinical Characteristics and Follow-Up Data for 37 Study Patients 
Age at 
Pt No./ Onset of QRS Axis Symptoms Pharmacologic Symptoms Other Follow-Up 
Gender Age (yr) VT (yr) During VT Before Therapy Therapy After Therapy Therapy Duration (yr) Outcome 
1/M 30 17 L Moderate Ver Mild - -  5.0 Alive 
2/F 38 11 L Moderate Prop Mild - -  13.3 Alive 
3/M 45 41 L Moderate Vet Mild - -  11.0 Alive 
4/M 41 29 L Moderate Ver Mild - -  10.8 Alive 
5/M 22 13 k Moderate Ver Mild - -  10.5 Alive 
6/F 25 23 k Mild None Mild - -  10.3 Alive 
7/F 23 11 k Mild None Mild - -  9.5 Alive 
8/M 12 12 L Severe Vet, PA Severe Antitachy 3.7 Dead 
9/M 41 41 L Mild None Mild - -  9.8 Alive 
10/F 36 36 L Moderate Ver, PA 0 - -  8.6 Alive 
l I/M 25 12 L Moderate Ver 0 - -  7.3 Alive 
12/F 31 27 L Moderate Ver Mild - -  8.3 Alive 
13/F 12 14 L Moderate Vcr Mild - -  7.2 Alive 
14/M 30 28 L Moderate Ver Mild - -  5.8 Alive 
15/F 19 13 L Mild None Mild - -  6.8 Alive 
16/M 63 48 L Mild None 0 - -  6.8 Alive 
17/M 22 16 L Moderate Dig 0 - -  5.4 Alive 
18/F 68 65 L Moderate Vet 0 - -  5.4 Alive 
19/M 40 40 L Mild None 0 - -  5.8 Alive 
20/M 33 30 L Mild None 0 - -  5.4 Alive 
21/M 29 29 L Mild None 0 - -  8.3 Alive 
22/M 19 19 L Severe Ver Severe CA 4.0 Alive 
23/M 37 29 L Mild None 0 - -  3.4 Alive 
24/M 31 15 L Moderate Ver Mild - -  3.1 Alive 
25/F 20 16 L Severe Ver Severe CA 2.3 Alive 
26/M 42 42 L Mild None Mild - -  3.0 Alive 
27/M 29 25 L Mild None Mild - -  2.7 Alive 
28/M 64 63 L Moderate Ver, PA 0 - -  2.2 Alive 
29/M 16 16 L Moderate Ver Mild - -  1.7 Alive 
30/M 53 45 L Mild None Mild - -  1.8 Alive 
31/M 49 39 L Severe Ver, Prop Severe Operation 10.0 Alive 
32/M 26 23 L Severe Ver Severe CA 1.5 Alive 
33/M 28 26 L Mild None 0 - -  1.1 Alive 
34/M 21 20 R Mild None 0 - -  8.3 Alive 
35/M 51 51 L Moderate Ver, Dig 0 - -  0.5 Alive 
36/M 18 16 L Severe Ver, Prop Severc CA 4.9 Alive 
37/F 30 26 R Moderate Prop Mild - -  0.7 Alive 
Antitachy = antitachycardia p cing device; CA = catheter ablation; Dig = digoxin; F = female; L = left-axis deviation; M = male; PA = procainamide; Prop = 
propranolol; Pt = patient; R = right-axis deviation; Ver = verapamil; VT = ventricular taehycardia; 0 = free of symptomatic ventricular tachycardia; - -  = nil. 
is shown in Figure 3. All patients remained alive, except for the 
one with the antitachycardia device. 
Discuss ion  
Effect of oral verapamil. Oral verapamil alone or in com- 
bination with other drugs was effective in alleviating the 
symptoms of most of our patients with moderate ventricular 
tachycardia. However, the patients with severe ventricular 
tachycardia were not helped by verapamil administration, and 
all eventually required nonpharmacologic treatment. The dis- 
crepancy between the effectiveness of intravenous and oral 
verapamil in the patients with severe ventricular tachycardia 
was probably related to differences in the drug concentration 
achieved through each route. The two patients who responded 
to digoxin were worthy of note. They were initially misdiag- 
nosed as having supraventricular tachycardia and were thus 
given digoxin, but this drug was actually able to prevent the 
initiation of ventricular tachycardia by ventricular stimulation 
in both patients. 
Nonpharmacologic treatment. There has been increasing 
interest in the nonpharmacologic treatment of tachyarrhyth- 
mias, including antitachycardia pacing, implantable automatic 
cardioverter-defibrillators and ablative techniques, such as 
catheter ablation or map-guided cryosurgery. In patients with 
recurrent sustained ventricular tachycardia who do not re- 
spond to antiarrhythmic therapy, surgical intervention also 
offers a reasonable alternative because the introduction of 
intraoperative mapping to localize the site of origin of ventric- 
ular tachycardia has improved the results. In our series, one 
JACC Vo l .  25 ,  No .  1 OHE ET  AL .  57  
January 1995:54-8  ID IOPATHIC  LEFT  VENTRICULAR TACHYCARDIA  
Figure 2. Electrocardiograms of ventricular 
tachycardia originating from the midapical 
inferior (A) and superior (B) left ventricle. A, 
Right bundle branch block (RBBB) and left- 
axis deviation (LAD). B, Right bundle branch 
block and right-axis deviation (RAD). pts = 
patients. 
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patient underwent cryosurgery, and the site for ablation was 
determined by activation mapping during ventricular tachycar- 
dia. The patient has subsequently remained free of symptom- 
atic ventricular tachycardia without antiarrhythmic drugs for 
10 years. 
Electrical catheter ablation is a relatively new method for 
the treatment of ventricular tachycardia. Unfortunately, the 
Figure 3, Actual survival rate for all 37 patients (Kaplan-Meier 
method). One patient died during follow-up. 
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success rate of catheter ablation is not high in patients with 
ventricular tachycardia (10). However, promising results have 
been achieved when catheter ablation is used to treat idio- 
pathic right (11) or idiopathic left (12) ventricular tachycardia. 
The optimal site for ablation was determined by pace mapping 
or by Purkinje potential recording during ventricular tachycar- 
dia in patients with idiopathic left ventricular tachycardia. In 
the present series, direct current catheter ablation was per- 
formed at the site determined by pace mapping during sinus 
rhythm. Three of the patients remained free of ventricular 
tachycardia, and one developed recurrence of the arrhythmia, 
which was controlled by verapamil. 
Most ventricular tachycardia can be terminated by pacing. 
However, antitachycardia pacing in ventricular tachycardia 
incurs the risk of inducing ventricular fibrillation (13). In this 
regard, the patient (Patient 8) unfortunately had an antitachy- 
cardia device implanted without a backup defibrillator while he 
was away from Osaka. 
Long-terra prognosis. The present study confirmed previ- 
ous findings (1,2) that idiopathic ventricular tachycardia has an 
excellent prognosis, suggesting that patients with verapamil- 
sensitive sustained left ventricular tachycardia probably should 
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be treated on a symptomatic basis. The patients with mild 
ventricular tachycardia remained mildly symptomatic without 
any therapy during follow-up. In contrast, the patients with 
severe ventricular tachycardia remained severely symptomatic 
despite verapamil therapy and required nonpharmacologic 
intervention. The patients with moderate ventricular tachycar- 
dia were likely to respond to verapamil, and such patients 
should be considered for oral verapamil therapy. However, 
radiofrequency ablation might become an alternative therapy 
for patients with moderate ventricular tachycardia because 
many patients prefer definite cure of their arrhythmia rather 
than long-term antiarrhythmic therapy. 
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